Research Based on Clinical Needs
１）Studies on Treatment and Prevention Methods to Alleviate Adverse Effects Induced by Anticancer Drugs
Chemotherapy-induced alopecia causes significant psychological distress in patients undergoing cancer treatment. Our laboratory is focusing on edaravone (EDR), a pharmaceutical agent with free radical scavenging and antioxidant properties, aiming to develop a method to suppress hair loss. Specifically, we use cyclophosphamide (CPA), a chemotherapeutic agent, to induce alopecia in experimental animals and investigate the effect of topical administration of EDR on hair loss prevention. If this effect is validated, it may minimize the psychological burden associated with chemotherapy-induced alopecia and contribute to more effective cancer treatment.
In addition, some anticancer agents can cause renal toxicity. Our research also seeks to elucidate the mechanisms underlying chemotherapy-induced nephrotoxicity and develop treatment strategies to prevent or mitigate its onset.
２）Research Aiming to Expand Drug Indications
We are investigating the effectiveness of intravenous administration of lipid emulsions as a detoxification method in cases of overdose with lipophilic drugs. Specifically, we are studying experimental models of clomipramine intoxication—a tricyclic antidepressant—and have found that preventive administration of lipid emulsions may suppress the onset of hypothermia and arrhythmia. We aim to further clarify the therapeutic effects and ultimately apply these findings in clinical settings.
Research on preventive and therapeutic strategies to effectively induce immune tolerance in allergic diseases (e.g., food allergy, allergic rhinitis)
The prevalence of food allergies and allergic rhinitis has been steadily increasing in recent years, highlighting the urgent clinical need for effective strategies for both prevention and treatment. In our laboratory, we utilize animal models of allergic diseases—including food allergy and allergic rhinitis—to develop efficient prophylactic strategies and therapeutic interventions. By elucidating the mechanisms through which these interventions promote immune tolerance, we aim to establish novel and effective methods for preventing and treating allergic diseases.
Research on therapeutic strategies to effectively induce complete remission in autoimmune diseases (e.g., Multiple Sclerosis, Rheumatoid Arthritis)
Multiple sclerosis and rheumatoid arthritis are chronic autoimmune diseases that typically follow a relapsing-remitting course. Although current therapies can induce remission, symptoms often recur after treatment is discontinued. Therefore, there is a pressing need for therapeutic strategies capable of achieving long-term, ideally complete, remission. In our laboratory, we utilize animal models of autoimmune diseases—multiple sclerosis and rheumatoid arthritis—to develop novel treatment strategies aimed at effectively inducing sustained and complete remission.
Collaborative Research with Clinical Institutions
１）A Study on the Factors and Predictors Leading to Discontinuation or Dose Reduction of Mineralocorticoid Receptor Antagonists (MRAs)
This study aims to identify the clinical factors and predictive indicators associated with the discontinuation or dose reduction of mineralocorticoid receptor antagonists in patients. Through retrospective analysis of clinical data, we seek to contribute to safer and more effective long-term use of MRAs in clinical practice.
２）A Survey on the Impact of Drug Shortages on Pediatric Medication Practices
This research investigates the real-world impact of pharmaceutical supply shortages on pediatric patients, focusing on how such shortages affect drug selection, administration methods, and treatment outcomes. By clarifying the extent and nature of these effects, we aim to provide evidence for healthcare policy and improve pediatric pharmaceutical care.
Staff
Professor: Takumi Tsuji, Ph. D.
Career History
2001- Graduated with a degree in Pharmacy, Faculty of Pharmaceutical Sciences,
Setnan University
2003- Completed Master's program in Pharmacy, Graduate School of Pharmaceutical
Sciences, Setsunan Universit
2003- Joined the Department of Pharmacy, Osaka Daini Keisatsu Hospital
(currently Kita Osaka Keisatsu Hospital)
2007- Assistant Professor, Laboratory of Pathophysiology, Faculty of Pharmaceutical
Sciences, Setsunan University）
2013- Lecturer, same department and faculty
2016- Associate Professor, same department and faculty
2025- Professor, same department and faculty
Career History
2008- Graduated with a degree in Pharmaceutical Sciences, Faculty of Pharmaceutical
Sciences, Setsunan University
2010- Completed Master's program in Pharmaceutical Sciences, Graduate School
of Pharmaceutical Sciences, Setsunan University
2010- Assistant Professor, same department and faculty
2017- Lecturer, same department and faculty
Research Achievements
2024
Yuya Yoshida, Koji Iijima, Mayumi Matsunaga, Mia Y Masuda, Min-Jhen Jheng,
Takao Kobayashi, Hirohito Kita.: Oral mucosa effectively protects against
peanut allergy in mice., J Allergy Clin Immunol. 154(4), 1060-1068. 2024.
Takumi Tsuji, Katsuaki Yoneda, Yu Igawa, Erika Minamino, Nodoka Otani, Yuya Yoshida, Takeyuki Kohno.: Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia., Cancer Chemotherapy and Pharmacology., 94(3), 467-473, 2024.
2022
Shohei Nakano, Norihisa Mikami, Mai Miyawaki, Saho Yamasaki, Shoko Miyamoto,
Mayu Yamada, Tomoya Temma, Yousuke Nishi, Arata Nagaike, Seijun Sakae,
Takuya Furusawa, Ryoji Kawakami, Takumi Tsuji, Takeyuki Kohno, Yuya Yoshida.:Therapeutic
Strategy for Rheumatoid Arthritis by Induction of Myeloid-Derived Suppressor
Cells with High Suppressive Potential. Biol. Pharm. Bull., 45(8), 1053-1060,
2022.
Tsuji, T., Hosoda, A., Toriyama, Y., Yoshida, Y., Kohno, T.:Renin-angiotensin
system inhibitors combined with cisplatin exacerbate cisplatin-induced
nephrotoxicity in mice. Elsevier , doi: 10.1016/j.tranon.2022., Published
online Apr. 4, 2022
Yoshida, Y., Banno-Terada, R., Takada, M., Fujii, T., Takagaki, N., Maekawa,
A., Tanaka, A., Endo, M., Yamada, A., Mamiya, R., Nagi-Miura, N., Ohno,
N., Tsuji, T., Kohno, T.:Sivelestat's effect on Candida albicans water-soluble
fraction-induced vasculitis. Pediatrics International, doi: 10.1111/ped.15153,
Published online Jan. 28, 2022
2021
Yoneda, K., Fujii, M., Imaoka, A., Kobayashi, R., Hayashi R., Yoshida,
Y., Kohno, T., Tsuji, T.:Preventive effect of edaravone ointment on cyclophosphamide-chemotherapy
induced alopecia．Support Care Cancer , doi: 10.1007/s00520-021-06189-7,
Published online Apr. 2, 2021
Tsuji T, Kuramoto N, Yasuhara T, Nishida K, Kuge T. Pharmacy Education,,
doi:10.24489/jjphe.2020-057, Published online Jan. 30, 2021
Nagata, M., Yasuhara, T., Kushihata, T., Ueda, A., Kurio, W., Sone, T.,
Kohno, T.: Construction of a Practical Disaster Prevention Drill Including
the Operation of Temporary Disaster Shelters and Rescue Centers at the
University and Application in Disaster Medical Education. Jpn. J. Pharm.
Edu., doi:10.24489/jjphe.2020-043, Published online Feb. 19, 2021.
Yoshida, Y., Mikami, N., Nakanishi, Y., Saimoto, M., Nagaike, A., Shimono,
H., Nakano, S., Tsuji, T., Kohno, T.: Characterization of an Expanded IL-10-Producing-Suppressive
T cell Population Associated with Immune Tolerance. Biol. Phar. Bull.,
doi:10.1248/bpb.b19-01072, Published online Jan. 26, 2021.
2020
Hosoda, A., Matsumoto, Y., Toriyama, Y., Tsuji, T., Yoshida, Y., Masamichi
S., Kohno, T.: Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity
in a Mouse Model. Biol. Pharm. Bull., 43(9), 1331-1337, 2020.
Ogushi, S., Yoshida, Y., Nakanishi, T., Kimura, T.: CpG Site-Specific Regulation
of Metallothionein-1 Gene Expression. Int J Mol Sci., doi:10.3390/ijms21175946,
Published online Aug. 19, 2020.
Iwasaki, A.,Sone, T.，Okuno, S., Maki, R., Kohno, T.：Learning strategies
to support pharmacy students' learning by hepatitis B virus-infected patients:
patient-participatory education where learning is linked and deepened with
empathy for patients.YAKUGAKU ZASSHI, 140(10), 1275-1284, 2020.